Author

A. Sieber

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1 Research Focus:trajectory inference· 1

Frequent Co-Authors

N. Bluthgen· 3 shared B. Klinger· 2 shared D. Beule· 2 shared E. Blanc· 2 shared M. Dorel· 2 shared A. Eggert· 1 shared A. Trinks· 1 shared B. Obermayer· 1 shared

Activity by Year

2016-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

N. Bluthgen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance

M. Dorel, B. Klinger, T. Mari, J. Toedling, E. Blanc, M. Nadler-Holly, M. Ziehm, A. Sieber, F. Hertwig, D. Beule, A. Eggert, J. H. Schulte, M. Selbach, N. Bluthgen

This study identifies feedback-mediated resistance to MEK inhibitors in neuroblastoma and shows that combining MEK with RAF or IGFR inhibitors can overcome resistance.

bioRxiv · Jun 14, 2021Cancer Biology

Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer

F. Uhlitz, P. Bischoff, S. Peidli, A. Sieber, B. Obermayer, E. Blanc, A. Trinks, M. Luethen, Y. Ruchiy, T. Sell, S. Mamlouk, R. Arsie, T.-T. Wei, K. Klotz-Noack, R. Schwarz, , M. Morkel

The paper identifies mitogen-activated protein kinase activity as a driver of cell trajectories in colorectal cancer using single-cell transcriptomics and organoid models.

bioRxiv · Jan 10, 2020Cancer Biology

Dissecting cancer resistance to therapies with cell-type-specific dynamic logic models

F. Eduati, V. Doldan-Martelli, B. Klinger, T. Cokelaer, A. Sieber, F. Kogera, M. Dorel, M. J. Garnett, N. Bluthgen, J. Saez-Rodriguez

The paper uses dynamic logic models of signaling pathways to predict drug sensitivity in colorectal cancer cell lines and identifies drug combinations to overcome resistance.

bioRxiv · Dec 16, 2016Cancer Biology